COVID-19 and myocarditis: a review of literature.

Author(s): Ali M; School of Medicine, The University of Manchester: Shiwani HA; Burnley General Hospital.
Source: The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2022 Apr 05; Vol. 74 (1), pp. 23. 
Abstract: Myocarditis has been discovered to be a significant complication of coronavirus disease 2019 (COVID-19), a condition caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. COVID-19 myocarditis seems to have distinct inflammatory characteristics, which make it unique to other viral etiologies. The incidence of COVID-19 myocarditis is still not clear as a wide range of figures have been quoted in the literature; however, it seems that the risk of developing myocarditis increases with more severe infection. Furthermore, the administration of the mRNA COVID-19 vaccine has been associated with the development of myocarditis, particularly after the second dose. COVID-19 myocarditis has a wide variety of presentations, ranging from dyspnea and chest pain to acute heart failure and possibly death. 

• Available here https://tehj.springeropen.com/track/pdf/10.1186/s43044-022-00260-2.pdf

​